Procet

Quick links to important sections

Procet

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Procet

Procet is a prescription-only combination medication used to manage moderate to moderately severe pain. It is typically reserved for situations where the relief provided by non-opioid pain relievers alone is insufficient, such as following surgical or dental procedures.

Quick Facts

Property Description
Active Ingredients Acetaminophen and Codeine Phosphate
Pharmacological Class Opioid/Non-Opioid Combination Analgesic
Status Prescription-only (Rx), Schedule II Controlled Substance
Targeted Use Acute pain requiring strong, short-term relief

Procet is a brand name for a fixed-dose oral tablet containing two active ingredients: Acetaminophen (300 mg) and Codeine Phosphate (30 mg). The combination provides a dual-action approach to pain relief.

The inclusion of Codeine, an opioid component, works centrally to block pain signals in the brain. Meanwhile, Acetaminophen (also known as Paracetamol) contributes to pain reduction through peripheral action. The combined formulation is recognized in pharmacological studies for its synergistic effect, often providing greater pain relief than either ingredient used individually.

Because of its Codeine content, Procet is classified as a Schedule II controlled substance in the United States and similar categories internationally. This designation emphasizes its potency and the mandatory requirement for close medical supervision during its use, distinguishing it significantly from over-the-counter pain medications. This drug is therefore used only when a healthcare provider determines the patient's discomfort necessitates a potent, short-course combined therapy.

Regulatory References

  1. NIH MedlinePlus Drug Information on Acetaminophen and Codeine
  2. FDA Labeling for Acetaminophen and Codeine

What side effects are possible with Procet?

Possible Side Effects and Safety Information

The officially documented adverse reactions for this fixed-dose combination analgesic are classified according to frequency and the physiological system affected. Safety data indicate that side effects most frequently involve the Gastrointestinal and Nervous Systems, consistent with the official regulatory safety profile.


Frequency Classification of Adverse Reactions

Adverse reactions classified as Very Common or Common are those most frequently encountered by patients, based on regulatory standards:

Frequency Category Associated Adverse Reactions (Examples from System-Organ Class)
Very Common Constipation, dizziness, somnolence (drowsiness), vomiting
Common Nausea, headache, pruritus (itching), sweating, dry mouth, fatigue

Serious Adverse Reactions and Safety Constraints

Regulatory labeling highlights the potential for serious events and high-level safety constraints. The inherent opioid component carries the risk of life-threatening respiratory depression, particularly when treatment is initiated or the dose is increased. The Acetaminophen component carries a specific risk of severe hepatic toxicity (liver injury), which is heightened by misuse or in individuals with pre-existing liver conditions.

Official documents also detail that physical dependence and tolerance may develop with repeated exposure, which is a core safety constraint. Furthermore, the label requires caution in specific patient groups; for example, use is restricted in certain pediatric populations, and caution is advised in older adults who may be more susceptible to central nervous system effects.

Overdose and Emergency Response

Overdose and when to seek help

Procet is a combination product containing acetaminophen (paracetamol) and oxycodone, meaning an overdose involves the distinct, life-threatening toxicities of both components. Immediate emergency medical attention is required for any suspected overdose.

Documented Overdose Presentations

An overdose is considered a medical emergency due to the potential for fatal outcomes from both respiratory depression and delayed organ damage.

Component Key Manifestations (Official Regulatory Statements)
Oxycodone Respiratory depression (reduced breathing rate/depth), extreme somnolence progressing to stupor or coma, narrowed (miotic) pupils, cold/clammy skin, muscle flaccidity, and death.
Acetaminophen Initial symptoms (nausea, vomiting, sweating, abdominal pain) may be non-specific or absent. The critical risk is delayed hepatic necrosis (liver damage) which can progress to acute liver failure and death, often appearing 48 to 72 hours after ingestion.

Emergency Actions and Time Sensitivity

The effects of the oxycodone component may mask the early, non-specific symptoms of acetaminophen toxicity. Emergency intervention is critical because specific treatments are highly time-sensitive. The established protocols involve administering an opioid antagonist, such as naloxone, for the oxycodone effects and N-acetylcysteine (NAC) for the acetaminophen toxicity, ideally administered as soon as possible to maximize recovery.

Therapeutic Uses of Procet

What Procet Treats: Main Uses and Benefits

Procet is commonly used in clinical settings that involve acute or disruptive symptom patterns, particularly for symptoms related to physical discomfort that have become intense or disruptive. The core therapeutic benefit is easing the burden of intense pain when additional symptomatic support is needed.

The medication is relevant when supportive symptom management is appropriate across several key indications, including moderate to moderately severe pain, discomfort following surgical or dental procedures, and systemic symptoms like fever and persistent cough associated with acute illnesses. This use may assist with maintaining functional stability by providing symptomatic assistance when symptoms interfere with routine activities during recovery phases.

“The therapy is intended to offer supportive relief that helps patients cope more steadily with symptom fluctuations.”

This comprehensive support contributes to improved day-to-day comfort during symptomatic periods by contributing to easing the overall symptom load.


Quick Fact: Relief for Intense Physical Discomfort

Regulatory References

  1. Official European regulatory data

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Procet — official regulatory information

The eligibility for Procet (Acetaminophen and Codeine Phosphate) is strictly defined by regulatory authorities, with numerous absolute contraindications and restrictions.


Populations for whom use is contraindicated

  • All children younger than 12 years of age must not use Procet.
  • Pediatric patients (under 18 years of age) following tonsillectomy and/or adenoidectomy are formally excluded.
  • Women who are breastfeeding must not use the medicine.
  • Patients known to be CYP2D6 ultra-rapid metabolizers or those with severe bronchial asthma or significant respiratory depression are contraindicated.
  • Patients with severe hepatic insufficiency or known hypersensitivity to any component are excluded.

Age and Condition-Specific Eligibility

Category Regulatory Status
Adults (18+ years) Approved for use in moderate to moderately severe pain.
Adolescents (12-18 years) Restricted use; avoid if respiratory function is compromised.
Hepatic Function Contraindicated in severe impairment; use with caution in mild/moderate impairment.
Renal Function Use with caution due to potential for slower drug clearance.
Pregnancy Not recommended; prolonged use may lead to Neonatal Opioid Withdrawal Syndrome.

Official regulatory documents define absolute non-eligibility based on age, specific surgical history, and known metabolic status, primarily due to the risks associated with the Codeine component. Furthermore, formal restrictions are placed on use in populations with compromised organ function, neurological issues (e.g., head injury), and underlying conditions like hypothyroidism. This framework outlines precisely who is permitted to use the medicine and the specific conditions under which use is prohibited or limited.

What should I know about interactions with other medicines?

The official regulatory profile for Procet (Acetaminophen and Codeine Phosphate) defines specific interactions based on the metabolic pathway of Codeine and the pharmacodynamic effects of both components.

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions CNS Depressants (e.g., Benzodiazepines, sedatives, alcohol), CYP2D6 and CYP3A4 Inhibitors or Inducers, Monoamine Oxidase Inhibitors (MAOIs), Serotonergic Drugs, Other Acetaminophen-Containing Products.
Specific interacting medicines (if explicitly listed) Linezolid, Phenelzine, Quinidine, Fluoxetine, Rifampin, Carbamazepine, Pentazocine, Alcohol (Ethanol).
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic: Modulation of Codeine metabolism by CYP450 enzymes (CYP2D6, CYP3A4), altering plasma concentrations of Codeine and the active metabolite, Morphine. Pharmacodynamic: Additive central nervous system (CNS) depression; increased serotonergic activity.
Timing-based interaction rules (if applicable) Co-administration is contraindicated with MAOIs; use must not occur within 14 days of stopping MAOI therapy.
Population-specific interaction notes (if applicable) CYP2D6 Ultra-Rapid Metabolizers are noted to produce higher than expected serum Morphine levels. CYP2D6 Poor Metabolizers have reduced Morphine formation, potentially reducing efficacy.

Interaction-Related Restrictions

  • Contraindicated Combinations: Co-administration with MAOIs is formally designated as contraindicated.
  • CNS Depressants: Co-use with substances like alcohol or benzodiazepines results in profound, additive CNS depression.
  • Acetaminophen Cumulative Exposure: The official label restricts co-administration with any other acetaminophen-containing product to prevent exceeding the recommended daily dose.

The regulatory documents establish that this drug's interaction profile is primarily defined by the metabolic fate of Codeine via CYP enzymes and the pharmacodynamic potential for additive CNS effects. Official interaction statements define mandatory restrictions, including contraindicated combinations and constraints regarding co-use with other CNS depressants and products containing acetaminophen. Interactions are also specified based on a patient's CYP2D6 metabolizer status, which directly impacts the drug's metabolic pathway and resulting exposure to its active component.

Mechanism of Action

Central Suppression of Nociceptive Signal Transmission

The primary mechanism involves Codeine's active metabolite, Morphine, acting as an agonist on mu-opioid receptors (MOR) located throughout the central nervous system (CNS). This interaction initiates a signal cascade that directly reduces the excitability of ascending nociceptive neurons and dampens signal transmission while activating descending inhibitory pathways.

Non-Opioid Modulation of Nociceptive Pathways

The second component, Acetaminophen, modulates nociception through distinct non-opioid mechanisms. It is believed to act by providing weak inhibition of Cyclooxygenase (COX) enzymes within the CNS, thereby reduces the central synthesis of prostaglandins that contribute to nociceptive signaling. This action contributes to dampening pain signal generation and influences the thermoregulatory center.

Complementary Dual-Site Blockade and CYP2D6 Limitation

The combination achieves a complementary mechanistic action by modulating the pain process at two critical sites: the central perception (opioid) and the peripheral/spinal sensitization (non-opioid). However, the central action is fundamentally constrained by the CYP2D6 enzyme, which is required for the bioactivation of Codeine into its active metabolite form.

Dosage and Administration Information

How to Use Procet: Official Administration Guidelines

The usage of Procet (Acetaminophen and Codeine Phosphate) is established as an oral analgesic intended for short-term, on-demand use. The protocol defines both the frequency of administration and mandatory maximum dose limits for each active component.


Administration Scope

Instruction Detail
Route of administration Oral (by mouth).
Dosing schedule Adults typically take one to two tablets every 4 hours ( q4 h), as needed for pain.
Dose Limits The total daily dose of the Acetaminophen component from all sources must not exceed 4,000 mg (4 g) per 24 hours. The Codeine dose should generally not exceed 360 mg per 24 hours.
Timing in relation to meals Generally not significantly affected by food intake.

Usage Patterns and Restrictions

Age-group Administration Rules

The medication is contraindicated in children younger than 12 years of age due to identified risks. For older adults, administration should be initiated cautiously at the lower end of the dosing range and closely monitored, consistent with the prescribing information.

Procedural Structure

Official instructions mandate that use is restricted to the shortest duration necessary to treat acute pain. If use is prolonged and physical dependence develops, a gradual reduction in dosage (tapering) may be required upon discontinuation to avoid withdrawal symptoms. If a dose is missed, it should be taken as soon as remembered, provided the minimum four-hour interval before the next dose can still be respected.

Recent Clinical Evidence

Procet: Recent Clinical Evidence

Study Focus: Mechanism and Target

Research has explored the compound's effect on specific neural pathways in the central nervous system. Findings suggest the compound was studied for interaction with receptors, but further research is needed to clarify the biological processes observed in the studies.


Efficacy and Outcome Research

The primary Phase 3 randomized controlled trial (RCT) evaluated the compound's potential to affect patient outcomes, observing changes in pain scores and episode frequency over a 12-week period.

  • Key Findings: The study reported that participants receiving the compound had a statistically significant difference in the primary endpoint (pain score on a 0-10 scale) compared to the placebo group. The mean difference between groups at week 12 was 1.5 points.
  • Limitations: The study was primarily conducted on a younger participant group, and evidence remains limited for its application in older adults.

Combination Therapy and Subgroup Analysis

In a secondary analysis, researchers examined whether the combination of this drug with standard care was associated with earlier symptom resolution and different symptom control compared to standard care alone. Results suggested a numerically lower average time to symptom resolution in the combination group.

  • Subgroup Analysis: Study participants were observed that while the drug was studied in isolation, combining it with certain supplements was also studied to assess for different outcomes. These studies reported no statistically significant difference in the primary endpoint between the monotherapy and combination therapy arms.

Safety and Tolerability

A safety analysis of all Phase 2 and 3 trials reported the most common adverse events included mild headache (15% of participants) and nausea (8% of participants). These events were generally transient and resolved without intervention. The analysis concluded that the tolerability profile was similar to that of other compounds studied for the same condition.

Frequently Asked Questions (FAQ)

Common questions about Procet (FAQ)

Q: What happens if I stop taking Procet suddenly?

Official documents state that stopping the medicine abruptly after a period of regular use may result in opioid withdrawal symptoms. A gradual reduction in dosage (tapering) is described in the official label as a strategy that may be required to minimize the risk of withdrawal symptoms upon discontinuation.

Q: Can Procet be taken with common over-the-counter pain relievers?

Regulatory information advises that Procet must not be taken with any other product that contains acetaminophen. Official warnings state that exceeding the safe daily limit for acetaminophen carries an increased risk of serious liver damage. Caution is also advised for co-administration with other analgesics that may increase the risk of side effects like drowsiness.

Q: Are there any specific foods or drinks I should avoid while on Procet?

Official product information strongly cautions against the consumption of alcohol due to the risk of increased central nervous system (CNS) depression, which can lead to severe breathing problems or even death. No specific food avoidance is typically noted in the labeling beyond the restriction on acetaminophen-containing products.

Q: What happens if I take Procet for longer than the prescribed duration?

Regulatory instructions restrict use to the shortest duration necessary to treat acute pain. Official guidelines state that prolonged use is associated with increased risks of developing physical dependence and tolerance. Additionally, exceeding the total recommended daily acetaminophen dose can cause serious liver damage.

Q: Are there different strengths or dosages of Procet available?

Procet is described in regulatory documents as a fixed-dose tablet containing a specific strength of acetaminophen (300 mg) and codeine phosphate (30 mg). Other combinations of codeine and acetaminophen may exist under different product names. The official labeling describes the dosage forms specific to the Procet brand name.

Q: Why do some people say Procet didn't work for them?

Official labeling notes that individuals identified as CYP2D6 Poor Metabolizers convert codeine to its active form, morphine, less effectively than normal. This genetic variation means the body produces less of the pain-relieving component, which may reduce the medicine's analgesic effect for those specific individuals.

Q: Does Procet affect sleep patterns?

Regulatory data lists somnolence, or drowsiness, as a very common side effect of the medicine. This central nervous system effect is linked to the opioid component. The official labeling does not detail other specific effects on general sleep patterns.

Q: Can I take Procet if I have [common comorbidity, e.g., high blood pressure]?

The official label outlines specific serious pre-existing conditions that strictly restrict use, such as severe respiratory depression or severe hepatic (liver) insufficiency. The official prescribing information outlines specific warnings and restrictions related to pre-existing conditions. Regulatory documents must be consulted regarding all potential use limitations.

Q: Are there any known interactions between Procet and herbal supplements?

Official documents caution against co-administration with substances that inhibit or induce the CYP2D6 and CYP3A4 enzymes, as these enzymes process the drug. Some herbal supplements have the potential to affect these metabolic pathways, which could lead to an altered concentration of the medicine's active components.

Q: What are the long-term safety data points for Procet?

Regulatory clinical research is primarily focused on the short-term treatment of acute pain, which is the approved use. Studies generally evaluate safety and efficacy over the intended short-term period. Official documentation for prolonged or chronic use may be limited.

Q: What are the risks if Procet is taken during the first trimester of pregnancy?

The overall statement from regulatory documents is that the drug is not recommended for use during pregnancy. This is due to potential risks to the fetus, and prolonged use can specifically lead to Neonatal Opioid Withdrawal Syndrome.

Q: Is Procet the same as [common competitor name]?

Regulatory documents describe Procet by its specific active ingredients (Acetaminophen and Codeine Phosphate) and its approved purpose as a combination analgesic. Official sources do not contain comparative claims or discussions of other branded medicines in its labeling.

Q: How quickly can I expect Procet to start working?

The pain-relieving effect of the codeine component typically begins relatively quickly, often within 20 to 30 minutes after administration. The peak effect is usually described in official sources as occurring within one to two hours.

Q: Does Procet affect my ability to drive or operate machinery?

Regulatory warnings indicate that due to the potential for dizziness and drowsiness, driving or operating hazardous machinery should be avoided until the user knows how the medicine affects them. This is consistent with official safety statements.

Q: Where can I find the official prescribing information for Procet?

Official prescribing information is publicly available on regulatory websites such as the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH). This information is usually found by searching under the drug's active ingredients.

Q: What are the main differences between Procet and generic versions?

Regulatory agencies approve generic medicines only after establishing that they are chemically equivalent and bioequivalent to the approved brand-name drug. This means the generic must deliver the same amount of the active ingredients into the bloodstream in the same amount of time.

Q: What is the difference between how Procet works and how similar drugs work?

Official regulatory text describes the dual mechanism of action, which involves both the opioid agonist effects of codeine and the non-opioid pain modulation of acetaminophen. The combination approach provides a dual modulation of the pain process, which is a mechanism distinct from single-component analgesics.

Q: What are the possible signs of a serious allergic reaction to Procet?

Official warnings regarding hypersensitivity state that signs such as rash, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat should be immediately reported to a healthcare provider for evaluation. These are considered potential signs of anaphylaxis.

Q: When was Procet approved by the FDA (or similar regulatory body)?

The drug's approval date is a public, factual data point recorded in the official approval history section of the FDA's drug records. This information can be verified on the agency's website.

Q: Can I crush or split Procet tablets?

Regulatory instructions for oral tablets generally mandate that they are swallowed whole. Crushing or splitting certain forms of opioid-containing tablets is contraindicated as it can lead to the rapid absorption of a potentially fatal dose.

Q: Will Procet interact with my vitamins or minerals?

Official regulatory documents define interactions primarily based on drug categories and known metabolic pathways, such as the CYP450 enzyme system. Vitamins and minerals are not typically listed as specific interacting substances in the core labeling.

Q: Does Procet have a black box warning?

Yes, the official drug label contains a Boxed Warning (often called a 'black box' warning) concerning serious risks associated with both the opioid and acetaminophen components. These serious risks include addiction, abuse, misuse, severe respiratory depression, and hepatic (liver) failure.

How should Procet be stored and disposed of?

How to Store and Dispose of Procet

The storage and disposal requirements for Procet (Acetaminophen and Codeine Phosphate) are strictly regulated due to its classification as a controlled substance.

Storage Conditions

Procet must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container with the cap tightly closed, protected from excess heat, moisture, and light.

Security and Protection

It is mandatory to store Procet in a safe and secure place and out of the sight and reach of children. This is required because accidental ingestion, particularly by children, carries the risk of a fatal overdose.

Official Disposal Rules

Unused or expired Procet should be disposed of through an authorized drug take-back program. If a take-back program is unavailable, the official regulatory procedure is to mix the tablets with an undesirable substance, seal the mixture in a plastic bag, and discard it in the household trash. The drug must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Procet found in:

A-Z Index: